Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Show me how to use this page

Scholar Rock Holding Stock

Price
Target price
€13.00

€13.00

-3.790%
-0.5
-3.790%
€21.76
 
25.04.24 / Tradegate WKN: A2JMQW / Symbol: SRRK / Name: Scholar Rock / Stock / Small Cap /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Scholar Rock Holding in the next few years
Wizard

Scholar Rock Holding Stock

Scholar Rock Holding took a tumble today and lost -€0.500 (-3.790%).
Scholar Rock Holding is currently one of the favorites of our community with 10 Buy predictions and no Sell predictions.
As a result the target price of 21 € shows a very positive potential of 61.54% compared to the current price of 13.0 € for Scholar Rock Holding.

Scholar Rock is a clinical-stage biopharmaceutical company that engages in the discovery and development of innovative medicines to treat serious diseases in patients that currently have limited or no treatment options. Their pipeline consists of a number of product candidates that target growth factor signaling pathways within the human body. These products hold potential for the treatment of multiple diseases, including neuromuscular disorders, cancer, and fibrosis. Scholar Rock, which trades under the symbol SRRK, is listed on the NASDAQ stock exchange.

Pros and Cons of Scholar Rock Holding in the next few years

Pros
?
C******** o* t** e**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Cons
?
B****
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Your Opinion
Legal notice

Comments

Prediction Buy
Perf. (%) -5.80%
Target price 18.498
Change
Ends at 03.04.25

Scholar Rock Holding Co. (NASDAQ: SRRK) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $20.00 price target on the stock.
Ratings data for SRRK provided by MarketBeat
Show more

Truist Financial Co. 
0
Report Share
03.04.24
Prediction Buy
Perf. (%) -11.56%
Target price 27.729
Change
Ends at 28.03.25

Scholar Rock Holding Co. (NASDAQ: SRRK) is now covered by analysts at Raymond James. They set a "strong-buy" rating and a $30.00 price target on the stock.
Ratings data for SRRK provided by MarketBeat
Show more

Raymond James 
0
Report Share
28.03.24
Prediction Buy
Perf. (%) -11.56%
Target price 25.794
Change
Ends at 26.03.25

Scholar Rock Holding Co. (NASDAQ: SRRK) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $28.00 price target on the stock.
Ratings data for SRRK provided by MarketBeat
Show more

Piper Sandler 
0
Report Share
26.03.24
Show more
Not a member yet? Sign up for free!

News

Scholar Rock Reports Full Year 2023 Financial Results and Highlights Business Progress: https://mms.businesswire.com/media/20211102005274/en/922183/5/Logo_2020.jpg
Scholar Rock Reports Full Year 2023 Financial Results and Highlights Business Progress


Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious

BusinessWire_EN 
0 19.03.24
Scholar Rock to Participate in Upcoming Investor Conferences: https://mms.businesswire.com/media/20211102005274/en/922183/5/Logo_2020.jpg
Scholar Rock to Participate in Upcoming Investor Conferences


Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious

BusinessWire_EN 
0 28.02.24
Scholar Rock Announces the Addition of Katie Peng to Its Board of Directors and Promotes Mo Qatanani, Ph.D. to Chief Scientific Officer: https://mms.businesswire.com/media/20211102005274/en/922183/5/Logo_2020.jpg
Scholar Rock Announces the Addition of Katie Peng to Its Board of Directors and Promotes Mo Qatanani, Ph.D. to Chief Scientific Officer


Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious

BusinessWire_EN 
0 15.02.24